BYRON E. HALL, M.D., F.A.C.P.; FORREST M. WILLETT, M.D., F.A.C.P.; DONALD R. HALES, M.D.
During the last few years, evaluation at the clinical level of the growth-inhibiting properties of various chemotherapeutic agents has demonstrated the lack of an easily definable pattern with which to predict what degree of growth-inhibitory action may be shown by any given compound under investigation among the broad spectrum of the neoplastic diseases. It is known that tissues with rapid rates of growth are more susceptible to injury by chemical compounds than are those with relatively slow rates of growth, but this generalization applies to normal tissues as readily as it does to malignant tissues. For example, the hemopoietic tissues
HALL BE, WILLETT FM, HALES DR. OBSERVATIONS ON THE EFFECTS OF ALKYLATING AGENTS IN HUMAN NEOPLASTIC DISEASE12. Ann Intern Med. 1960;52:602–625. doi: 10.7326/0003-4819-52-3-602
Download citation file:
© 2019
Published: Ann Intern Med. 1960;52(3):602-625.
DOI: 10.7326/0003-4819-52-3-602
Hematology/Oncology.
Results provided by: